Larkspur Biosciences has announced the dosing of the first participant in its Phase 1 clinical trial of LRK-4189 with Quotient Sciences - Nottingham.
LRK-4189 is a first-in-class targeted protein degrader designed to treat microsatellite stable colorectal cancer and other solid tumors. This milestone marks an important step toward addressing one of the most challenging cancer subtypes, accounting for approximately 85% of all colorectal cancer cases in the U.S.
The study, conducted by Quotient Sciences at our Nottingham clinic, will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of LRK-4189 in healthy volunteers. By starting in healthy participants, Larkspur aims to define a biologically meaningful dose before moving into patient studies.
Quotient Sciences is proud to play a critical role in this program, managing the clinical trial and overseeing recruitment of healthy volunteers. Our integrated approach accelerates early-phase development, helping innovative companies like Larkspur Biosciences bring transformative therapies to patients faster and improve patient outcomes.